Tab 3: Examples of altered sensitivity of cell lines to different cytotoxic drugs or radiation following manipulation of either survivin function or cellular levels.
| Cell line/tissue | Strategy/ survivin (down or up) | Therapy | Effect on therapy | Reference |
| MCF-7 | mutant/down | taxol | enhanced | 84 |
| MCF-7 | siRNA/down | taxol | enhanced | 92 |
| multiple breast cancer cell lines and patient samples | ASODN/down | taxol | enhanced | 91 |
| MCF-7 | RA/down | taxol | enhanced | 94 |
| MCF-7, T-47D and MDA-MB-231 | Prodigiosin/down | taxol | enhanced | 95 |
| MCF-7 xenograft model | flavopiridol/down | Adriamycin, Taxol, or UVB | enhanced | 96 |
| MCF-7 and MDA-MB-435 | calcium sensing receptor/down | taxol | enhanced | 99 |
| MCF-7 tumor nodules or tumor-bearing peritoneum | mutant/down | =taxol,>adriamycin | 84 | |
| MDA-MB-231 | stat3inhibition/down | radiation | enhanced | 102 |
| BT-474 | 17-AAG/down | radiation | enhanced | 103 |
| MDA-MB-231 | deguelin/down | radiation | enhanced | 104 |
RA, retinoic acid.